WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets

Breakthrough

Natera takes a Breakthrough designation for a multi-cancer blood test

MedDevice Startups Staff · Oct 9 · 2 min read · Via BioSpace (Natera press release)

FDA granted Breakthrough Device designation to Natera's multi-cancer early detection assay, the Austin company said October 9. The test reads cell-free DNA in blood to screen for several cancers at once.

Natera says FDA reviewed data across 12 cancer types, covering sensitivity, specificity and cancer signal origin performance. It did not name the assay or publish the numbers. Alexey Aleshin, the company's corporate chief medical officer, said too many cancers are found after they have progressed.

Designation buys sprint-level access to reviewers, not a lower bar. It is worth more here than usual, because the agency is still settling how to judge a test that screens for many cancers at once. An FDA panel split 6 to 4 on the effectiveness of GRAIL's Galleri on September 23, and every question raised there lands on Natera next.

Questions & Answers

What did FDA grant Natera for its multi-cancer early detection test?

FDA granted Breakthrough Device designation to Natera's multi-cancer early detection assay, announced October 9, 2026. The test analyzes cell-free DNA in blood to screen for multiple cancers.

What data did FDA review for Natera's MCED designation?

Natera says FDA reviewed data covering 12 cancer types, including sensitivity, specificity and cancer signal origin performance. Natera did not name the assay or release the underlying figures.

Does Breakthrough Device designation lower the evidence bar for Natera?

No. Breakthrough designation gives a company faster and more frequent FDA interaction during development and review, and it applies to PMA, De Novo and 510(k) submissions. Natera still has to meet the same evidence standard at the time of its submission.

← Back to Regulatory